MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10165-012-0658-1

Медицинская библиотека · Modern rheumatology · 2012

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.

Takamura Akito, Hirata Shintaro, Nagasawa Hayato, Kameda Hideto, Seto Yohei, Atsumi Tatsuya, Dohi Makoto, Koike Takao, Miyasaka Nobuyuki, Harigai Masayoshi

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

We investigated associations between treatment with methotrexate (MTX) or biological disease-modifying antirheumatic drugs (DMARDs) and elevation of serum Krebs von den Lungen-6 (KL-6) levels in Japanese patients with rheumatoid arthritis (RA).

METHODS

Using a standardized form, data were collected retrospectively from medical records and analyzed descriptively.

RESULTS

Of a total of 198 RA patients with KL-6 serum levels measured at initiation of treatment (month 0) and two or more times by month 12, 27 (17.9 %) of 151 RA patients treated with biological DMARDs, including infliximab, etanercept, adalimumab, and tocilizumab (the biological DMARDs group), and 5 (10.6 %) of 47 patients treated without biological DMARDs but with MTX (MTX group), met criterion B (max. KL-6 ≥500 U/ml and >1.5-fold from baseline) by 12 months. The majority of patients (n = 28) meeting criterion B had no apparent interstitial lung disease or malignancy. Of these 28 patients, 21 had serum KL-6 levels available after reaching their maximum level, and 13 (61.9 %) of the 21 then met criterion R [decrease to less than 500 U/ml or to less than (baseline + 0.5 × (maximum - baseline))] by month 12.

CONCLUSION

Serum KL-6 levels may increase during treatment with MTX or these biological DMARDs without significant clinical events.

Для цитирования: Takamura Akito, Hirata Shintaro, Nagasawa Hayato, Kameda Hideto, Seto Yohei, Atsumi Tatsuya, Dohi Makoto, Koike Takao, Miyasaka Nobuyuki, Harigai Masayoshi. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.. Modern rheumatology. 2012. DOI: 10.1007/s10165-012-0658-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.